Purdue Fends Off Generic OxyContin Competition
Endo Pharmaceuticals has agreed to end its patent infringement lawsuit with Purdue, which has raged from the Southern District of New York to the Federal Circuit and back. The suit nearly cost Purdue its OxyContin patent.
Endo has agreed to stop selling its generic by the end of 2006, and in exchange, Purdue...
To view the full article, register now.